lopinavir/ritonavir, ribavirin and interferon beta-1b for COVID-19 - living meta-analysis of clinical studies

meta|evidence COVID-19

Living systematic review and meta-analysis

vs. potential COVID-19 treatments
vs. antiviral and associated therapy
vs. lopinavir/ritonavir

All
COVID 19 hospitalized
COVID 19 all comers
COVID-19 mild to moderate
COVID-19 severe or critically
COVID 19 outpatients
COVID-19 (hospitalized or not)
COVID-19 prophylaxis (children)
COVID-19 prophylaxis (excluding children)
infections other than COVID-19
Long COVID-19
preventing respiratory virus transmission
root
secondary prevention

Studies
Mapping
Meta-analysis
Excluded 0

table network network 2

display ongoing demontrated benefit only

popup

University of Hong Kong, 0 NCT04276688

lopinavir/ritonavir, ribavirin and interferon beta-1b vs. lopinavir/ritonavir

COVID 19 all comers

Hung et al., 2020 NCT04276688

lopinavir/ritonavir, ribavirin and interferon beta-1b vs. lopinavir/ritonavir

COVID-19 mild to moderate

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -

Extraction panel open

An extraction panel is open